PolyPid to Announce Q3 2024 Financial Results and Highlights on November 13, 2024

PolyPid Ltd., a late-stage biopharmaceutical company based in Petach Tikva, Israel, is set to disclose its financial results and operational updates for the third quarter of 2024. The announcement will be made prior to the opening of U.S. financial markets on Wednesday, November 13, 2024. Following the release, the company plans to host a conference call and webcast at 8:30 AM Eastern Time to discuss their performance and future business endeavors.

To facilitate a smooth connection for participants, PolyPid recommends registering at least five minutes before the scheduled start of the call. The company advises those who do not intend to ask questions to join via the webcast for a seamless experience.

PolyPid Ltd., listed on Nasdaq under the ticker PYPD, focuses on enhancing surgical outcomes through its advanced pharmaceutical solutions. Their proprietary technology, PLEX (Polymer-Lipid Encapsulation matriX), is designed for the local administration and controlled, prolonged release of therapeutics. This system pairs with Active Pharmaceutical Ingredients (APIs) to ensure precise drug delivery at optimal release rates, which can last from several days to several months.

The company’s flagship product candidate, D-PLEX100, is currently undergoing a Phase 3 clinical trial aimed at preventing infections in abdominal colorectal surgeries. Alongside this, PolyPid is in the preclinical stages of developing OncoPLEX, a treatment targeting solid tumors, with initial tests focused on glioblastoma.

For more detailed information about PolyPid and their innovative medical solutions, interested parties are encouraged to visit their official website and follow their updates on social media platforms like Twitter and LinkedIn.